Summary
Cencora, Inc. (formerly AmerisourceBergen Corporation) reported strong revenue growth in the first quarter of fiscal year 2023, driven primarily by its U.S. Healthcare Solutions segment. This segment saw a significant increase in revenue, largely attributed to unit volume growth and increased sales to major customers, despite a decline in COVID-19 treatment sales. The company's International Healthcare Solutions segment experienced a slight revenue decrease, impacted by a prior divestiture and unfavorable foreign currency exchange rates, though partially offset by contributions from recent acquisitions and ongoing business. While gross profit saw a modest increase, total operating expenses rose due to higher administrative, restructuring, and amortization costs. The company also completed a significant acquisition of PharmaLex, enhancing its global services capabilities, and announced a forthcoming investment in OneOncology. The ongoing opioid litigation remains a significant financial and operational consideration, with a substantial liability accrued.
Financial Highlights
55 data points| Revenue | $63.46B |
| Cost of Revenue | $61.16B |
| Gross Profit | $2.30B |
| SG&A Expenses | $1.32B |
| Operating Income | $560.52M |
| Net Income | $435.40M |
| EPS (Basic) | $2.15 |
| EPS (Diluted) | $2.13 |
| Shares Outstanding (Basic) | 202.32M |
| Shares Outstanding (Diluted) | 204.26M |
Key Highlights
- 1Revenue increased by 9.9% year-over-year to $63.5 billion for the three months ended March 31, 2023, primarily driven by the U.S. Healthcare Solutions segment's 11.3% growth.
- 2Gross profit increased by 2.7% to $2.3 billion for the quarter, positively impacted by both reporting segments and antitrust litigation settlement gains.
- 3Total operating expenses increased by 19.2% to $1.7 billion, driven by higher distribution, selling, administrative, restructuring, and amortization expenses.
- 4The company acquired PharmaLex Holding Gmbh for $1.473 billion, adding specialized services to its International Healthcare Solutions segment.
- 5Net income attributable to AmerisourceBergen Corporation was $435.4 million, a decrease from $548.0 million in the prior year quarter, impacted by increased operating expenses and a lower effective tax rate.
- 6The company's balance sheet shows robust current assets of $40.0 billion, though current liabilities also remain high at $45.1 billion, mainly due to accounts payable.
- 7Significant cash outflow from investing activities ($1.6 billion) was largely due to the PharmaLex acquisition, while financing activities also showed a net outflow.
- 8The company ended the quarter with $1.69 billion in cash, cash equivalents, and restricted cash, a decrease from $3.59 billion at the beginning of the period.